Compare MIST & MFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIST | MFC |
|---|---|---|
| Founded | 2003 | 1887 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 60.8B |
| IPO Year | N/A | 1999 |
| Metric | MIST | MFC |
|---|---|---|
| Price | $2.05 | $36.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 10.0M | 1.9M |
| Earning Date | 11-12-2025 | 02-18-2026 |
| Dividend Yield | N/A | ★ 3.44% |
| EPS Growth | N/A | ★ 10.85 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $22,912,074,891.00 |
| Revenue This Year | N/A | $34.60 |
| Revenue Next Year | N/A | $8.50 |
| P/E Ratio | ★ N/A | $16.17 |
| Revenue Growth | N/A | ★ 6.09 |
| 52 Week Low | $0.63 | $25.92 |
| 52 Week High | $3.06 | $36.93 |
| Indicator | MIST | MFC |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 62.19 |
| Support Level | $1.94 | $36.46 |
| Resistance Level | $2.14 | $36.85 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 30.24 | 60.78 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 22% of adjusted earnings. The Asia segment operates across 12 countries and contributes around 36% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 23% of earnings. Manulife's global asset and wealth management business contributes approximately 20% of its earnings and had around CAD 1.03 trillion in assets under management and administration as of the end of 2024.